FDAnews
www.fdanews.com/articles/196529-emas-chmp-recommends-compassionate-use-for-remdesivir

EMA’s CHMP Recommends Compassionate Use for Remdesivir

April 3, 2020

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued its recommended conditions for compassionate use of Gilead’s antiviral remdesivir for treatment of COVID-19.

The committee said that the drug should be used for adult patients who require invasive ventilation devices.

The compassionate use conditions do not apply to patients under 12 years of age or to patients with hypersensitivity to the drug, multiorgan failure, renal failure or participation in other COVID-19 trials.